欧洲过敏和临床免疫学会重症哮喘生物制剂治疗指南解读

Interpretation of European Academy of Allergy and Clinical Immunology Biologicals Guidelines-Recommendations for severe asthma

由于疾病的异质性、合并症、护理的复杂性以及国家或地区卫生保健系统之间的差异,重症哮喘的管理十分困难。重症哮喘给患者、家庭及医疗系统带来了沉重的疾病负担。基于目前对哮喘机制的深入了解,提出生物制剂对重症哮喘靶向治疗的相关概念。仍需对重症哮喘治疗过程中生物制剂的选择、有效性的定义、提高有效性的方法、治疗持续时间及治疗方案等方面进一步阐述。

Severe asthma imposes a significant burden on patients,families,and healthcare systems.Management is difficult,due to disease heterogeneity,co-morbidities,complexity in care pathways and differences between national or regional healthcare systems.Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma,supporting the use of targeted treatments with biologicals.However,there are still many issues that require further clarification.These include selection of a certain biological,the definition of response,strategies to enhance the responder rate,the duration of treatment and its regimen.